MX2024010596A - Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas - Google Patents

Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas

Info

Publication number
MX2024010596A
MX2024010596A MX2024010596A MX2024010596A MX2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A
Authority
MX
Mexico
Prior art keywords
compositions
methoxy
acylethanolamines
meai
aminoindane
Prior art date
Application number
MX2024010596A
Other languages
English (en)
Spanish (es)
Inventor
Adi Zuloff-Shani
Original Assignee
Clearmind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Medicine Inc filed Critical Clearmind Medicine Inc
Publication of MX2024010596A publication Critical patent/MX2024010596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024010596A 2022-03-07 2024-08-29 Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas MX2024010596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317257P 2022-03-07 2022-03-07
PCT/IB2023/052091 WO2023170552A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Publications (1)

Publication Number Publication Date
MX2024010596A true MX2024010596A (es) 2025-01-09

Family

ID=85706794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010596A MX2024010596A (es) 2022-03-07 2024-08-29 Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas

Country Status (9)

Country Link
US (1) US20250302773A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489741A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508052A (cg-RX-API-DMAC7.html)
CN (1) CN119212690A (cg-RX-API-DMAC7.html)
AU (1) AU2023231494A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244360A1 (cg-RX-API-DMAC7.html)
IL (1) IL315486A (cg-RX-API-DMAC7.html)
MX (1) MX2024010596A (cg-RX-API-DMAC7.html)
WO (1) WO2023170552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024062395A1 (en) * 2022-09-21 2024-03-28 Clearmind Medicine Inc. Use of 5-methoxy-2-aminoindan ("meai") in methods for treating metabolic syndrome
WO2025196662A1 (en) * 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
ES2139750T3 (es) 1993-08-06 2000-02-16 Upjohn Co 2-aminoindanos como ligandos selectivos d3 de la dopamina.
WO2005002524A2 (en) * 2003-07-02 2005-01-13 The Regents Of The University Of California COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
WO2016092546A1 (en) * 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
CA3244360A1 (en) 2023-09-14
WO2023170552A1 (en) 2023-09-14
US20250302773A1 (en) 2025-10-02
IL315486A (en) 2024-11-01
CN119212690A (zh) 2024-12-27
EP4489741A1 (en) 2025-01-15
JP2025508052A (ja) 2025-03-21
AU2023231494A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
SA523440574B1 (ar) مثبطات إنترليوكين-17
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
CL2023002698A1 (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
BR112022005736A2 (pt) Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
JOP20230275A1 (ar) معدلات trex1
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos